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Introduction
Erdheim-Chester disease (ECD) is a rare non-
Langerhans cell histiocytosis firstly described in
1930,1 since then in no more than 500 cases. It has
multiple organ involvement characterized by fi-
brosclerotic and inflammatory feature, typically in-
volving the orbits and the retro-orbital tissue in 25%
of cases, mostly bilaterally, determining exophthal-
mos, retro-orbital pain, oculomotor paralysis and loss
of vision.2 It is characterized by a progressive course
although the recent discovery of a BRAF V600E mu-
tation in more than half of the cases allowed imple-
menting specific therapies thus changing prognosis.3,4
We present a case of ECD with previous history of
pseudotumor cerebri with bilateral orbital involve-
ment, where the evidence of a multisystem involve-
ment on fibrotic-inflammatory basis led to the
suspicion and then to the diagnosis of the disease.
Written informed consent was obtained from the
patient for publication of this Case report and any ac-
companying images.
Case Report
A 63-years-old Caucasian woman was hospitalized
in our unit for malaise, vomiting for about a week and
signs of systemic inflammation. Her pathological his-
tory was characterized by a residual left hemiparesis
due to poliomyelitis in childhood and an episode of is-
chemic stroke in the right ponto-mesencephalic site
during a previous hospitalization when she was 54.
She was also diagnosed as suffering from chronic
pansinusitis with orbital extension, binocular manifes-
tation of retro-orbital pseudotumor and bilateral apical
pulmonary fibrosis with traction bronchiectasis.
In 2013 she performed oculist consult for the wors-
ening of the ophthalmological disease, which diag-
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nosed bulbar proptosis with conjunctival chemosis and
widespread corneal opacity. She also underwent oto-
laryngologist and maxillo-facial surgery consult with
biopsy of the maxillary sinus whose culture test was
negative and histological examination proved: Fi-
brovascular tissue with inflammatory infiltrate char-
acterized by lymphocytes, foamy histiocytes and
congestive phenomena. Unfortunately she refused fur-
ther diagnostic investigations. In addition she reported
history of progressive immobilization and osteoartic-
ular pain mostly in the legs.
On admission the patient was in poor general clin-
ical condition, alert, lucid, partially cooperative and
oriented in space and time, normal breathing, slowed
speech, supine obliged, blind and with hearing loss.
She complained of nausea, vomiting, and exacerbation
of osteoarticular pain.
The physical examination showed pallor and dehy-
dration of the skin and mucous membranes, bilateral
bulbar proptosis with conjunctival chemosis and puru-
lent secretions (Figure 1), muscle wasting in the lower
limbs with complete ankylosis of the left knee joint and
partial ankylosis of the right one. Blood tests showed
neutrophilic leukocytosis, increased inflammatory
markers, mild normochromic normocytic anemia, mild
hyponatremia and hypoalbuminemia (Table 1). Ac-
cording to the medical history an esophagus-gastro-
duodenoscopy and a total body computerized
tomography (CT) with contrast were performed to re-
assess the already known neurological and ocular pic-
tures and to identify a possible occult thoracic or
abdominal malignancy. Endoscopy proved negative,
whereas CT showed an increased volume of choroid
plexus of the temporal horn of the left lateral ventricle,
presence of solid retrobulbar tissue at the level of both
maxillary sinuses with diffuse bone rehash, apical pul-
monary fibrosis associated with bronchiectasis, pres-
ence of solid tissue wrapping the left top bronchus and
circumferential thickening of the walls of the infrarenal
abdominal aorta (Figure 2).
A brain magnetic resonance (MR) was also per-
formed with evidence of diffuse transcompartmental
splanchnic and intracranial hypointensity, on T2W se-
quences, and enhancement after contrast, on T1W, in
particular the choroid plexus, the paranasal sinuses,
the parapharyngeal structures and the left carotid
space with significant pre-occlusion (Figure 3).
A total body positron-emission tomography (PET)
further defined the multiorgan thoracic and abdominal
involvement. Unfortunately, it was not possible to per-
form a long bone x-ray due to lack of cooperation of
the patient who could not assume an appropriate posture
for the investigation as a result of ankylosis of lower
limb and osteoarticular pain during postural changes.
In the suspicion of a fibrotic histiocytic systemic
disease, we asked for a revision of the previous max-
illary sinus biopsy; our pathologists confirmed the al-
ready known inflammatory infiltrate but the
immunohistochemical evaluation identified a specific
CD68 positivity and CD1a negativity, compatible with
the diagnosis of ECD.
During the hospitalization it was administered a sys-
temic antibiotic therapy with quinolones and a local oc-
ular aminoglycoside, low-dose steroid and analgesics
with steady improvement in the local eye inflammatory
picture and in the systemic inflammatory indexes. For
the gastrointestinal symptoms levosulpiride and dom-
peridone were administered with improvement of nau-
sea and cessation of vomiting. Once the diagnosis was
achieved, the patient was addressed to a reference cen-
ter of immunology and rheumatology to undertake spe-
cific therapy and subsequent follow up.
After three months, we contacted the patient’s rel-
atives to know her conditions, but they reported a lack
of will to pursue the path of follow-up and treatment
suggested.
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Figure 1. Bilateral bulbar proptosis with conjunctival chemosis and purulent secretions.
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Discussion
In our report, the multiorgan involvement and the
specific tropism for perivascular and fatty connective
tissue, together with the CD68+ and CD1a– histology,
suggested the diagnosis of ECD. The rarity, the variable
clinical presentation and the lack of knowledge about
this disease make its identification a real challenge for
physicians.1 Clinical and radiographic features can di-
rect the diagnosis, but the clinical spectrum ranges from
asymptomatic forms to clinical frameworks character-
ized by extensive infiltration and multisystem organ
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Table 1. Laboratory parameters at admission and discharge.
Laboratory tests                                   Entrance                          Discharge                              Unit                        References values
Erythrocytes                                           3,780,000                           3,520,000                             106/mL                                 3.8-5
Hemoglobin                                                 11                                     10.2                                   g/dL                                  12-16
Hematocrit                                                  31.1                                    28.5                                     %                                    35-48
MCV                                                          82.3                                    83.9                                     fL                                    80-99
MCH                                                          29.1                                     29                                       pg                                    26-32
Leukocytes                                               17,910                                10,260                                103/mL                                 4-11
Neutrophils                                                 65.3                                    58.8                                     %                                    40-74
Lymphocytes                                              26.8                                    28.8                                     %                                    20-48
Monocytes                                                   6.9                                      4.8                                      %                                     3-11
Eosinophils                                                  0.9                                      7.3                                      %                                      0-8
Basophils                                                     0.1                                      0.3                                      %                                     0-1.5
Platelets                                                   326,000                              267,000                               103/mL                              150-450
Azotemia                                                     29                                       10                                   mg/dL                                10-50
Creatinine                                                    0.5                                      0.5                                   mg/dL                             0.51-0.95
Sodium                                                       131                                     135                                  mEq/L                              136-145
Potassium                                                    3.8                                     4.02                                  mEq/L                               3.3-5.1
Calcium                                                       9.9                                     9.08                                  mg/dL                              8.4-10.2
Sideremia                                                     31                                       52                                    mg/dL                                37-145
Ferritin                                                        802                                     237                                  ng/mL                               15-150
Transferrin                                                  144                                     195                                  mg/dL                              200-360
CRP                                                             5.7                                      3.8                                   mg/dL                                 0-0.5
Fibrinogen                                                  580                                     402                                  mg/dL                              150-450
Albumin                                                      3.1                                      3.0                                   mg/dL                               3.5-5.5
MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; CRP, C-reactive protein.
Figure 2. Enhanced abdomen computed tomography (CT) image showing the periaortic concentric soft tissue infiltration
(A). Thoracic CT images showing apical lung fibrosis and bronchiectasis associated with the presence of solid tissue that
like a sleeve wraps the left upper bronchus (B, C).
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failure. BRAF V600E mutation, an activating mutation
of the proto-oncogene BRAF, has been recently identi-
fied in more than half of ECD patients, in accordance
with a probable clonal origin of this disease.3 In parallel,
in ECD patient compared to controls, it was found the
expression of a proinflammatory cytokines pattern re-
sponsible for local activation and recruitment of histio-
cytes, with consequent elevated levels of interferon
(IFN)-a, interleukin (IL)-2, monocyte chemotactic pro-
tein-1 and decreased IL-4 and IL-7.5
According to the most recent consensus guide-
lines2 the diagnosis is based on:
-  Histology: foamy or lipid- laden histiocytes with ad-
mixed or surrounding fibrosis. On immunohisto-
chemical staining, histiocytes are positive for CD68,
CD163, and Factor XIIIa, and negative for CD1a and
Langerin (CD207). Positivity for S100 has been ob-
served rarely. This differentiates ECD from Langer-
hans cell histiocytosis (LCH), where Langerhans
cells are positive for CD1a, S100, and Langerin.2
-  Skeletal abnormalities: symmetric diaphyseal and
metaphyseal osteosclerosis of the long bones of the
legs on X-ray or symmetric and abnormal intense
labeling of the distal ends of the long bones of the
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Figure 3. Axial T2 and T1 weighted with contrast magnetic resonance image. Hypointense tissue on T2 and enhancement
after contrast on T1 in choroid plexus in the temporal horn of the left lateral ventricle involving orbital compartment
bilaterally (A, B), foramina of Luschka, terminations of the lower portion of the fourth ventricle and the maxillary
sinuses bilaterally (C, D).
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legs revealed by bone scintigraphy.2 Bone lesions
may also be visualized less sensitively on CT, MR
or PET imaging.6
Besides the skeletal involvement, present in more
than 90% of patients, almost all organs are affected:
-  Cardiovascular events: the most common manifes-
tation is the circumferential involvement of thoracic
and abdominal aorta with soft tissue called coated
aorta. If renal artery is involved, it could develop
renovascular hypertension.7 Pericardium may be in-
volved in 40-45% of patients with pericarditis, peri-
cardial effusion until tamponade. In one third of
patients there can be infiltration pseudotumor of the
right atrium. Cases of myocardial infarction by
coronary involvement are described.7,8
-  Pulmonary manifestations: In about half of the cases
there is the involvement of lung and pleural
parenchyma with thickening of interlobular septa,
ground-glass opacities, centrilobular and pleural
opacities, until the pulmonary fibrosis.9
-  Nervous system and orbital manifestations: The
nervous parenchyma may be diffusely infiltrated, so
also hemispheric pachymeninx and cerebellar ten-
torium, as a meningioma. Then a generalized cog-
nitive and motor function impairment can take
place, symptoms of cerebellar nature ataxia and
dysarthria, and in the case of orbits infiltration, ex-
ophthalmos, retro-orbital pain, oculomotor palsy
and blindness.10
   The infiltration of the orbits can be unilateral or bi-
lateral, it occurs in 25% of patients and has to be
distinguished from the ophthalmopathy during
Graves’ disease, granulomatous diseases, lymphoma
and giant cell arteritis.11
-  Endocrine manifestations: In 25% of patients severe
endocrinopathies occur including diabetes insipidus,
hyperprolactinemia and hypopituitarism.12
-  Retroperitoneal events: In 30% of patients, it is pos-
sible to find striking images of retroperitoneal fibro-
sis and infiltration of the perirenal tissue with the
typical feature of hairy kidney.2
-  Skin manifestations: the most common is repre-
sented by xanthelasmas, yellowish maculopapular
lesions on the face, neck, armpits and trunk present
in one third of patients.2
The differential diagnosis is mainly with LCH and
Rosai-Dorfman disease, with which it shares the infil-
trative multisystem inflammatory involvement and the
chronic-progressive trend but from which it differs for
the peculiar skeletal involvement and the histopathol-
ogy findings (Table 2).3
Other diseases that must be excluded are lym-
phomas, sarcoidosis, vasculitis, particularly Wegener’s
granulomatosis and Horton’s arteritis. In all this cases
the histology is diriment for diagnosis.
Unfortunately, to date, there are no curative thera-
pies for ECD. The first-line treatment consists of IFN-
a (or pegylated-IFN). It was shown that IFN-a is the
only treatment increasing patients survival,13 even if
there are no randomized controlled trials on the effi-
cacy of the drug. Treatment regimens ranges from
3,000,000 to 9,000,000 units three times a week de-
pending on the level of organ involvement, therapeutic
response and tolerability of the drug.13
Alternatively to IFN-a, PEG-IFN is usually ad-
ministered at doses of 135-200 mg per week.13
IFN-a efficacy, however, is not the same on all the
manifestations of the disease. Greater efficacy has
been reported for the bone, skin, retro-orbital and pi-
tuitary localizations.14 Forms with cardiac, pulmonary
and central nervous system involvement, which have
the most unfavorable prognosis,9,13,14 are less respon-
sive and higher IFN-a doses may be necessary. Given
the response variability as a consequence of organ in-
volvement, for more severe forms alternative thera-
peutic approaches have been tested. One of the most
promising is vemurafenib, a BRAF inhibitor. The ra-
tional use of this drug is based on the pathogenic hy-
pothesis of a clonal origin of the disease. In 54% of
patients with ECD was demonstrated the presence of
BRAF V600E mutation at the level of histiocytes.3 Ve-
murafenib is effective in forms with severe multisys-
tem involvement, refractory to IFN.4 Additional
therapeutic alternative is represented by infliximab, a
monoclonal anti tumor necrosis factor (TNF)-a anti-
body. TNF-a was, in fact, shown to play an important
role in the regulation of the inflammatory pattern char-
acterizing ECD. Infliximab has been proven especially
in forms with cardiovascular involvement that less re-
spond to IFN-a. The treatment was effective, both in
terms of symptoms and recovery of cardiac func-
tion.14,15 These treatments have been tried only on a
limited number of patients and there are not yet avail-
able data on their efficacy and safety in the long term,
for which further studies are required. Corticosteroids
are traditionally used because of their anti-inflamma-
tory action but have very limited effectiveness in
ECD. Bisphosphonates may be employed for the treat-
ment of bone lesions. On some disease manifestations,
such as skin and bone lesions, a discrete effect has
been reported for anakinra, IL-1 receptor antagonist.15
In our case, the patient was admitted because of
gastrointestinal symptoms accompanied by signs of
systemic inflammation, however, she showed clear
signs of an infiltrative orbital and retro-orbital disease
which had previously led to the diagnosis of retro-or-
bital pseudotumor.
Besides the neurological and orbital pictures to
drive the suspicion of a multisystem disease there
were the poor overall clinical conditions and the signs
of systemic inflammation.
The execution of a deeper radiological investiga-
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tion and the evidence of the typical multisystem in-
volvement allowed identification of a link between the
initial neuro-ophthalmology diagnosis and the more
complex picture, with fibrotic histiocytic genesis, fi-
nally diagnosed.
Helpful was also a previous retro-orbital tissue
biopsy that already revealed the presence of the foam
cells, typical of the ECD. According to the most recent
diagnostic criteria, biopsy was re-examined by immuno-
histochemical analysis, proving compatible with ECD.
Peculiar was the retro-orbital and orbital involve-
ment but also the extensive involvement of the neuro
and splanchnocranium, especially choroid plexus, si-
nuses, para-pharyngeal structures and left carotid
space with non-symptomatic pre-occlusion. The evi-
dence of apical pulmonary fibrosis, extending to the
left upper bronchus, wrapped sleeve by fibrotic tissue,
the extensive involvement of the retroperitoneal space
and the abdominal aorta testified an evolved disease
condition. The previous clinical findings and diagnos-
tic evaluations might have suggested a more detailed
systemic evaluation in particular at the time of retro-
orbital pseudotumor and bilateral apical pulmonary fi-
brosis with traction bronchiectasis diagnosis.
It is important to focus on the clinical and radio-
logical findings that may be bound to a fibrotic and
inflammatory pathology with contemporary involve-
ment of the brain, thoracic, abdominal and bone dis-
tricts. The diagnosis of retro-orbital pseudotumor
imposes more diagnostic tests in order to identify pos-
sible signs of multiple districts extension of the fi-
brotic process. A mention deserves gastrointestinal
disorders that led the patient to the admission in our
department. Esophagus-gastro-duodenoscopy ex-
cluded an organic genesis of vomiting, which resolved
with symptomatic treatment and together with the res-
olution of local and systemic inflammatory state. The
orbital and retro-orbital inflammatory state and the
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Table 2. Systemic histiocytic disorders of adults.3
                                                                        ECD                                                      LCH                                                     RDD
Histopathological features
CD68                                                                  1                                                             1                                                           1
CD163                                                                1                                                             1                                                           1
CD1a                                                                   2                                                             1                                                           2
CD207                                                                2                                                             1                                                           2
S100                                                           2 or weakly                                                     1                                                           1
Factor XIIIa                                                        1                                                             2                                                           2
Touton giant cells                                               1                                                             2                                                           2
Other characteristic features        Xanthomatous features                   Birbeck granules on electron           Intracytoplasmic lymphocytes
of lesional histiocytes                                  Fibrosis                                               microscopy                                       (emperipolesis)
Organ system involvement
Skin                                                           Xanthelasma                              Scaly erythematous patches                    Firm, indurated papules
                                                      Yellow or red-brown plaque
Heart                                                    Pericardial effusion                       Reported, but uncharacteristic             Reported, but uncharacteristic
                                            Myocardial infiltration right atrial mass,
                                                Periaortic sheathing (coated aorta)
Lungs                                           Interlobular septal thickening,                 Nodular and cystic changes               Reported, but uncharacteristic
                                                     ground-glass or centrilobular                   in upper and middle lobes
                                                                opacities on CT
Retroperitoneum                               Perinephric infiltration                     Reported, but uncharacteristic             Reported, but uncharacteristic
Liver and spleen                                               Rare                        Uncommon but constitutes high-risk disease  Reported, but uncharacteristic
Bone                                                       Femurs and tibia                     Craniofacial bones, proximal limbs,         Reported, but uncharacteristic
                                                                    Bone pain                                           pelvis, scapula
Lymph nodes                               Reported, but uncharacteristic    Uncommon but constitutes high-risk disease     Cervical, axillary, inguinal
CNS                                            Cerebellar or brain stem lesions            Cerebellar or brain stem lesions                    Dural-based lesions
                                                             Dural-based lesions                               Dural-based lesions
                                                       Brain parenchymal lesions                    Brain parenchymal lesions
                                                                                                               Non-infiltrative neuro-degeneration
ECD, Erdheim-Chester disease; LCH, Langerhans cell histiocytosis; RDD, Rosai-Dorfman disease; CT, computerized tomography; CNS, central nervous system.
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bulbar and intracranial hypertension, can justify those
gastric symptoms.
Antibiotic and steroid treatment solved the context
of acute inflammation, however it was not possible to
observe the subsequent evolution of the disease after
discharge because of the suggested follow-up inter-
ruption at the rheumatology center of reference.
Conclusions
This case demonstrates that the diagnosis of ECD
is not easy despite the presence of some clinical and
radiological typical signs, not always recognized and
traced to this rare disease.
The presence of a retro-orbital pseudotumor, espe-
cially if in combination with multifocal fibrosis, should
lead to suspicion of this condition, then to the subsequent
histological and immunohistochemical confirmation.
A prompt diagnosis and an adequate staging of the
disease allow the implementation of a specific therapy
with positive effects on prognosis, otherwise certainly
unfavorable.
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